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Abstract
The UL97 kinase has been shown to phosphorylate and inactivate the retinoblastoma protein (Rb)
and has three consensus Rb-binding motifs that might contribute to this activity. Recombinant
viruses containing mutations in the Rb-binding motifs generally replicated well in human foreskin
fibroblasts with only a slight delay in replication kinetics. Their susceptibility to the specific UL97
kinase inhibitor, maribavir, was also examined. Mutation of the amino terminal motif, which is
involved in the inactivation of Rb, also renders the virus hypersensitive to the drug and suggests
that the motif may play a role in its mechanism of action.
Findings
Human cytomegalovirus (HCMV) is a ubiquitous virus
that can be problematic in immunocompromised popula-
tions, including individuals with AIDS or recipients of
allograft transplants. It is the most common congenital
infection in the United States [1] and sequela include per-
manent neurological deficits, including hearing loss [2,3].
Ganciclovir (GCV), foscarnet and cidofovir (CDV) have
all been approved for the treatment of HCMV infection,
but each drug is associated with dose-limiting toxicities
[4]. The benzimidazole L-riboside maribavir (MBV) is cur-
rently in Phase III clinical trials for the treatment of HCMV
infections and inhibits viral replication by a distinct
mechanism involving the direct inhibition of UL97 kinase
activity [4-7]. While this drug clearly inhibits the enzy-
matic activity of the UL97 kinase in infected cells, the con-
sequences of its inhibition are complex and incompletely
understood as the kinase affects many cellular and viral
processes.
The UL97 serine/threonine kinase is expressed early in
infection and is found within the tegument of infectious
virions [8,9]. Although the kinase is not required for viral
replication, null mutants exhibit severe replication defi-
cits [10], which is consistent with the inhibitory effects of
MBV [5]. This enzyme has been shown to phosphorylate
viral proteins including itself, ppUL44 and pp65 [11-13],
as well as the large subunit of RNA polymerase II, eukary-
otic elongation factor 1delta, P32 and lamins A/C [14-16].
The tumor suppressor retinoblastoma (Rb) has also been
shown to be hyperphosphorylated in cells infected with
HCMV [17], and this phosphorylation is dependent on
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UL97 kinase activity [18]. This report also showed that
mutations in either the essential lysine (K355) or the con-
served LxCxE Rb-binding motif in the amino terminus of
pUL97 reduced the inactivation of Rb [18]. A separate
study showed that the kinase phosphorylated Rb directly
and did not require other proteins [19]. This activity is
intriguing since Rb is also targeted by many viruses,
including human papilloma virus, simian virus 40, and
adenovirus [20]. However, the interaction seems to be
finely-tuned between HCMV and the cell and does not
appear to result in an oncogenic phenotype exhibited by
other viruses which target Rb.
Rb belongs to the family of pocket proteins which prevent
the progression of the cell through the G1/S checkpoint by
binding to and suppressing the function of the transcrip-
tion factor E2F; hyperphosphorylation of Rb causes it to
release E2F which activates key steps in the cell cycle [21].
The inactivation of Rb by the kinase is presumed to mod-
ify cell checkpoint protein expression and induce the
expression of cellular proteins required for viral infection,
but its impact on viral replication has not been estab-
lished. The UL97 gene product contains three consensus
binding sequences for Rb [18,19]; disruption of the essen-
tial lysine or the amino terminal Rb-binding motif
(LxCxE) reduces the Rb phosphorylation seen in HCMV
wild type (wt) inoculated cells [18]. Therefore, we hypoth-
esized that viruses with disrupted Rb-binding sites in the
UL97 kinase might have an impaired replication pheno-
type or altered susceptibility to antiviral drugs.
Recombinant viruses were engineered with point muta-
tions in the UL97 open reading frame (ORF) and their
construction was reported previously [18]. RC314 is a
kinase-null virus with a K355M mutation. Recombinants
RC295, RC312, and RC316 contain amino acid substitu-
tions C151G (LxCxE), C428G (LxCxD) and C693G
(IxCxE), respectively, that disrupt individual putative Rb-
binding elements in the amino acid sequence of UL97.
Another virus was constructed that contains both the
C151G and the C428G mutations (RC323). Replication
kinetics of each of these viruses were evaluated in low
MOI infections of stationary HFF cells in the presence of
2% FBS. Disruption of the essential kinase motif in the
UL97 ORF with a K355M mutation severely impacted the
replication of the virus and was indistinguishable from
that of RCΔ97 [Figure 1A]. This confirmed that the
absence of kinase activity was responsible for the replica-
tion deficiency in the deletion mutant [10], and is consist-
ent with results published previously [18]. Disruption of
individual Rb binding motifs had minimal impact on
virus replication in a 14-day time course [Figure 1B].
Growth curves for RC312, RC295, RC316, and RC323
were similar to that of the wt virus (HB5), although there
appeared to be a slight delay at 4 and 5 days post infec-
tion, with RC295 having the lowest titers. This result was
repeatable and was confirmed in a second independent
experiment with these viruses (data not shown). The dou-
ble-mutant virus (RC323) also exhibited a minor replica-
tion delay in a separate experiment [Figure 1C]. These data
suggest that the mutation of these sites has a minimal
effect on viral replication.
A second set of viruses was constructed that contained a
secreted alkaline phosphatase (SEAP)-expression cassette
at US6 (T2211) [22]. The LxCxE motif was disrupted with
a C151 deletion (T3038) and pUL97 was truncated at
codon 536 to yield a null mutant (T2266). Replication of
these viruses was assessed in human embryonic lung
(HEL) cells infected at an MOI of 0.01–0.03 PFU/cell, and
SEAP supernatant activity was determined with a chemilu-
minescent substrate. No detectable differences were
observed between the wt virus (T2211) and the UL97
ΔC151 virus (T3038) [Figure 1D]. The UL97-truncated
virus (T2266) replicated poorly and had growth character-
istics similar to those of RC314, and confirmed that
defects in kinase activity could be detected in these stud-
ies. Results from both experiments indicated that muta-
tion of the LxCxE motif did not severely impact virus
replication. The minor delay in virus replication was not
apparent in the T3038 and is likely related to assay differ-
ences. We conclude that the disruption of each of the Rb
binding motifs individually or of the two amino terminal
motifs in tandem has only minor effects on viral replica-
tion in cell culture. However, we cannot exclude the pos-
sibility that the disruption of all three may impact growth
or that replication may be more compromised in other
systems.
The mutations also had the potential to impact the effi-
cacy of MBV and GCV, so the susceptibility of the mutants
was determined by standard plaque reduction assays [23].
MBV was obtained from the National Institute of Allergy
and Infectious Diseases (NIAID), CDV was a gift from
Gilead Sciences and GCV was obtained from University of
Alabama, Birmingham Hospital Pharmacy. All of the
viruses were equally susceptible to the CDV control and
was expected since this nucleotide analog does not require
initial phosphorylation by the UL97 kinase [Table 1]. The
kinase null virus, RC314, exhibited reduced susceptibility
to GCV and MBV and is similar to results reported previ-
ously for RCΔ97 [23]. None of the viruses with mutations
in the Rb binding motifs exhibited significant differences
in their sensitivity to GCV, and confirmed that the muta-
tions did not impact the enzymatic activity of the kinase.
Interestingly, the disruption of the amino terminal LxCxE
motif in RC295 rendered it modestly hypersensitive to
MBV, which suggests that the Rb binding motif might be
related to the mechanism of action of MBV. This is con-
sistent with a previous report, which showed only thisVirology Journal 2009, 6:9 http://www.virologyj.com/content/6/1/9
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motif appeared to impact Rb phosphorylation [18]. It was
not clear, however, why this mutation did not affect MBV
susceptibility of the double mutant, but this effect was dif-
ficult to measure because of the assay-to-assay variability
with this virus.
To confirm these data, the susceptibility of the SEAP-
reporter viruses was also evaluated against GCV and MBV
using SEAP activity as a surrogate marker of viral replica-
tion. Data were obtained by infecting confluent HEL
fibroblasts at an MOI of 0.01–0.03 PFU/cell and SEAP
activity in the supernatant was determined 6 days follow-
ing infection [24]. MBV sensitivity data are the average of
8 determinations from 3 independent experiments for the
T3038 and T2211 viruses tested simultaneously; the GCV
EC50 values are consistent with historical data and are
Growth curves of HCMV recombinants with mutations in UL97 Figure 1
Growth curves of HCMV recombinants with mutations in UL97. HFF cells were infected at an MOI of 0.01 PFU/cell 
and titers of the resulting progeny virus in cell lysates were determined at the indicated times. (A) Both a UL97-deleted virus 
(black triangles) and a null mutant with a K355M mutation (open circles) replicate poorly compared to the HB5 parent virus 
(black circles). (B) Replication kinetics of recombinant viruses with mutations in putative Rb-binding sites were determined and 
exhibit a slight delay in replication. Shown are the average titers from 2 replicate cultures with error bars representing the 
standard deviation values. RC295 (open circles) contains a mutation in the LxCxE motif, RC312 (black triangles) has a mutation 
in the LxCxD motif, RC316 (open triangles) carries a mutation in the IxCxE motif, and titers of the parent virus are shown as 
black circles. (C) RC323 (open circles) contains mutations in both the LxCxE and the LxCxD motifs and is shown with HB5 as 
a control (black circles). (D) Growth curves of SEAP-expressing HCMV recombinants with mutations in UL97 were examined 
separately; shown is the average SEAP activity of 5 replicates with the error bars representing the standard deviations. Replica-
tion of the wild-type virus with a SEAP-expression cassette (black circles) is similar to that of the recombinant virus with a 
deletion of codon 151 which disrupts the LxCxE motif (open circles), and both replicate much better than the virus with a 
truncation of the UL97 open reading frame (black triangles).Virology Journal 2009, 6:9 http://www.virologyj.com/content/6/1/9
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shown as the average of triplicate determinations. These
data confirmed that the disruption of the amino terminal
Rb-binding domain resulted in significantly increased
sensitivity to MBV. While the EC50 values differ between
the plaque reduction assays and the SEAP assays, both
assays are consistent in that they both show that disrup-
tion of the amino terminal Rb binding motif results in
increased susceptibility to MBV. These suggest that the
mechanism of action of MBV may involve the LxCxE Rb
binding motif and is consistent with the idea that the pre-
vention of Rb inactivation by MBV might be an important
aspect of its mechanism of action.
Disruption of the central cysteines in the UL97 Rb-bind-
ing motifs does not result in a severe replication deficiency
reminiscent of kinase null viruses, but rather results in a
very modest delay in viral replication. This might suggest
that the inactivation of Rb is not a crucial function in HFF
or HEL cells and that it may be important only in vivo.
Alternatively, it is possible that the motifs are redundant
and all of them must be deleted to impact replicative abil-
ity of the virus. Nevertheless, the C151G mutation in the
RC295 virus and the C151 deletion in the T3038 virus
clearly conferred hypersensitivity to MBV when compared
to their isogenic controls. While potential mechanisms for
this are unclear, it indicates that mechanism of action of
the drug is related to the function of the amino terminal
Rb-binding motif at some level. Additional experiments
will be required to assess the potential impact of double
and triple mutants. Nonetheless, these findings offer
insight into a new aspect of MBV activity and additional
studies with the inhibitor together with genetic studies
will help define the function of the kinase in viral infec-
tion.
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